Cemtrex heads into its May 19 earnings report with a lending market that has cooled sharply from its April extremes — but not enough to signal any real comfort for short sellers.
The most striking data point is the collapse in cost to borrow. In early April, borrowing CETX shares cost north of 340% annualised. By May 14 that figure had dropped to 69.5% — still expensive by any normal standard, but a fraction of where it was six weeks ago. Short interest has followed a similar downward arc, falling roughly 64% over the past month to 8.7% of the free float, after spiking as high as the equivalent of nearly 118% when measured against a very thin float in the April data. Availability in the lending pool has loosened substantially as borrow demand has unwound, though the 52-week record shows this stock has hit full utilisation before, and conditions can tighten fast on small floats.
The price itself tells a harsher story. CETX has fallen 34% over the past month to $0.80, dropping another 10% in the past week alone. That decline tracks with the broader unwind in short-side activity — as the stock fell, some of the urgency to maintain large short positions diminished — but the ORTEX short score remains elevated at 70.5 out of 100, ranking in the second percentile of the broader universe. That score has barely moved over the past two weeks despite the headline reduction in short shares, suggesting the residual positioning is still concentrated and the structural bear thesis has not gone away.
Past earnings prints have been uniformly punishing. The last three confirmed events saw CETX fall between 5% and 13.5% in the following session, with five-day losses running as deep as 20%. The one outlier in the history was a 31% single-day spike, quickly followed by a partial reversal. That volatility profile reflects what micro-cap, thinly traded companies with tight floats tend to produce around reporting dates — large moves in either direction, with outsized short-term reversals.
Institutional ownership is sparse. Cambridge Investment Research holds the largest disclosed position at roughly 1.9% of shares, with the rest of the top-ten holders holding fractions of a percent. Insider data is too dated — the last recorded CEO purchase was in June 2023 — to carry any analytical weight heading into this print. What Tuesday's release will test most directly is whether Cemtrex can demonstrate any operational progress credible enough to interrupt the stock's month-long slide, or whether the residual short base finds fresh justification.
See the live data behind this article on ORTEX.
Open CETX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
